BIOLASE Added to Two Major Indices for 2013

BIOLASE Added to Two Major Indices for 2013 
Widely-Followed Russell 3000 and Russell Global Indices Will Include
Index-Following Funds Expected to Include Approximately 2.5-3.0
Million BIOL Shares via Market Purchase to Meet Their Rebalancing
Requirements by the Actual Rebalancing Date of June 28, 2013 
IRVINE, CA -- (Marketwired) -- 06/17/13 --   BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading manufacturer and distributor of dental
lasers, announced that Friday, June 14th as of 6:00 pm NYT it has
been disclosed by Russell to have been preliminarily chosen to be
added to the 2013 versions of the Russell 3000 Index (Russell Ticker:
RUA, Bloomberg Ticker: RAY) and the Russell Global Index (Russell
Ticker: RGIUSD, Bloomberg Ticker: RGI). Russell captures 98% of the
dollar volume of the tradable market for U.S. institutional equity
products that report a benchmark. With $4.1 trillion in assets
benchmarked, more U.S. institutional funds track Russell indexes than
all other U.S. equity indexes combined. 
The Russell 3000 Index measures the performance of the largest 3,000
U.S. companies, with a mean market capitalization of $1.2 billion. It
is constructed to provide a comprehensive, unbiased, and stable
barometer of the broad market and is reconstituted annually to ensure
new and growing equities are reflected. For the 2013 rebalancing, 64
companies had left the index via mergers or acquisition activity, 93
companies were deleted, and 157 new companies were added. BIOLASE is
one of the 157 new companies added to the Index. 
The Russell Global Index is intended to represent the investable
global equity market by market capitalization. It includes some
10,000 securities in 47 countries. For the 2013 rebalancing, a net of
37 companies had left the index via mergers or acquisitions, 769
companies were deleted, and 806 new companies were added. BIOLASE is
one of the 806 new companies added to the 2013 Russell Global Index.  
"The inclusion of our company in the widely-followed Russell 3000 and
Russell Global Indices is the result of the substantial growth in our
business since new Management and Board of Directors took over in
August 2010," said Federico Pignatelli, Chairman and CEO of BIOLASE.
"We know that a number of institutional funds use these indices for
their buying guidelines. Indeed, a May 31, 2013 research report from
Cantor Fitzgerald predicted that if we are included in this year's
Russell indices, an additional 2.5 million to 3.0 million BIOL shares
will be purchased to be included by June 28th 2013 for Index-based
funds' compliance with their own guidelines." 
"We are honored to be included in the Russell 3000 because of the
statement this makes about investor recognition of the prosperity and
growth of BIOLASE. We also welcome the upcoming comparison that being
in the index will bring us with last year's top-performing component
companies, such as Affymax, Inc., Vanda Pharmaceuticals, and Mannkind
Corp.," said Alexander Arrow, MD, President and COO of BIOLASE. "As
our business progresses the way we strategically plan over the next
twelve months and beyond, and BIOLASE is recognized by investors for
the value we are creating, I anticipate that we will be named one of
the year's top-performers by the time of next year's Russell Index
Please note: Russell's U.S. Indexes cover 98% of the U.S. equity
investable universe and include companies determined to be part of
the U.S. equity market according to Russell's robust country
classification methodology. All Russell U.S. Indexes are subsets of
the Russell 3000(R) Index, which includes the well-known large cap
Russell 1000(R) Index and small cap Russell 2000(R) Index.  
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment and CAD/CAM intraoral scanners; products
that are focused on technologies that advance the practice of
dentistry and medicine. The Company's proprietary laser products
incorporate over 350 patented and patent-pending technologies
designed to provide biologically clinically superior performance with
less pain and faster recovery times. Its imaginative products provide
cutting-edge technology at competitive prices to deliver the best
results for dentists and patients. BIOLASE's principal products are
revolutionary dental laser systems that perform a broad range of
dental procedures, including cosmetic and complex surgical
applications, and a full line of dental imaging equipment. BIOLASE
has sold more than 22,500 lasers. Other laser products under
development address ophthalmology and other medical and consumer
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at, Facebook at, Twitter at,
Pinterest at, LinkedIn at, Instagram at and YouTube at 
BIOLASE(R) and WaterLase(R) are registered trademarks of BIOLASE,
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995
 Statements contained in this press release that refer to
BIOLASE's estimated or anticipated future results or other
non-historical facts are forward-looking statements, as are any
statements in this press release concerning prospects related to
BIOLASE's strategic initiatives, product introductions and
anticipated financial performance. Forward-looking statements can
also be identified through the use of words such as "anticipates,"
"expects," "intends," "plans," "believes," "seeks," "estimates,"
"may," "will," and variations of these words or similar expressions.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which reflect BIOLASE's current
perspective of existing trends and information and speak only as of
the date of this release. Actual results may differ materially from
BIOLASE's current expectations depending upon a number of factors
affecting BIOLASE's business. These factors include, among others,
adverse changes in general economic and market conditions,
competitive factors including but not limited to pricing pressures
and new product introductions, uncertainty of customer acceptance of
new product offerings and market changes, risks associated with
managing the growth of the business, and those other risks and
uncertainties that may be detailed, from time-to-time, in BIOLASE's
reports filed with the SEC. BIOLASE does not undertake any
responsibility to revise or update any forward-looking statements
contained herein. 
For further information, please contact:
Michael Porter
Porter, LeVay & Rose, Inc.
Press spacebar to pause and continue. Press esc to stop.